DUBLIN–(BUSINESS WIRE)–The “Tinnitus – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Tinnitus – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Tinnitus (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Tinnitus (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 5 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Tinnitus (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tinnitus (Ear Nose Throat Disorders).
- Classify potential new clients or partners in the target demographic. (Read more…)
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tinnitus (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Introduction
- Report Coverage
Tinnitus – Overview
Tinnitus – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
Tinnitus – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Tinnitus – Companies Involved in Therapeutics Development
- AudioCure Pharma GmbH
- Auris Medical Holding Ltd
- Autifony Therapeutics Ltd
- Cognosetta Inc
- Gateway Biotechnology Inc
- Knopp Biosciences LLC
- Otonomy Inc
- Sensorion SA
Tinnitus – Drug Profiles
AC-102 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
AM-102 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
AUT-3 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Drugs for Tinnitus – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
gacyclidine – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
GW-103 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
GW-201 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
KB-3061 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Peptides to Target Calcium Activated Potassium Channel for Tinnitus – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
RL-81 – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Small Molecules to Activate KCNQ2 and KCNQ3 for Tinnitus – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Small Molecules to Inhibit TNF-Alpha for Tinnitus – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Small Molecules to Target Calcium Activated Potassium Channel for Tinnitus – Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Tinnitus – Dormant Projects
Tinnitus – Discontinued Products
Tinnitus – Product Development Milestones
- Featured News & Press Releases
- Jul 06, 2020: Otonomy reports positive top-line results from phase 1/2 clinical trial of OTO-313 in patients with tinnitus
- Jan 10, 2020: Auris Medical announces notice of allowance for European Patent Application
- Apr 11, 2019: Otonomy initiates phase 1/2 Clinical Trial of OTO-313 in Tinnitus
- Feb 06, 2019: Otonomy announces presentation on tinnitus drug OTO-313 at Association for Research in Otolaryngology Annual Meeting
Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/jsv8aj
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900